Allergy Diagnostics Market - By Product & Service (Consumables, Instruments, Services), By Test Type (In Vivo, In Vitro), By Allergen (Inhaled Allergens, Food Allergens, Drug Allergens), By End-use (Diagnostic Laboratories), & Forecast, 2023

Description

List of Tables

Global Allergy Diagnostics Market is poised for substantial growth over 2023-2032, driven by the rising prevalence of allergies worldwide and the burgeoning demand for accurate and efficient diagnostic tests.

With a growing number of individuals experiencing allergies, there is a greater need for early detection and effective management. Technological advancements in diagnostic techniques, such as molecular diagnostics and immunoassays, have improved the accuracy and specificity of allergy tests. Besides, increasing awareness among healthcare professionals and patients about the benefits of early diagnosis and personalized treatment will contribute to market growth. This apart, supportive government initiatives and favorable reimbursement policies are encouraging the adoption of allergy diagnostics, further propelling the market forward.

The allergy diagnostics market is segregated based on product & service, test, allergen, end-use, and region.

Regarding product & service, the market size from the services segment will amass decent gains through 2032. The demand for allergy diagnostic services is growing due to the increasing prevalence of allergies worldwide. With more individuals experiencing allergic reactions, there is a greater need for accurate and timely diagnosis to ensure proper management and treatment. Additionally, advancements in diagnostic technologies and rising awareness among healthcare providers and patients are further driving the demand for these services.

Based on the test, the allergy diagnostics market share from the in-vitro segment is anticipated to expand at a notable CAGR from 2023 to 2032. In vitro allergy diagnostics offer several advantages over traditional methods, such as quick and accurate results, allowing for early detection and personalized treatment plans. These tests are non-invasive, cost-effective, and provide comprehensive information about specific allergens, driving their increasing adoption in the field of allergy diagnostics.

With respect to the allergen, the market value from the drug allergen segment will witness commendable growth over 2023-2032. With the increasing use of medications, there is a higher risk of developing drug allergies. Accurate and reliable allergy tests are essential for identifying drug allergens, ensuring patient safety, and guiding appropriate treatment decisions. Additionally, breakthroughs in diagnostic technologies and increased awareness among healthcare professionals contribute to the growing demand for drug allergen testing.

Regionally, Europe allergy diagnostics industry is slated to accumulate a sizeable revenue share by 2032. There is a rising prevalence of allergies in Europe, leading to an increased need for accurate diagnosis and management. Additionally, growing awareness among healthcare professionals and patients, in line with supportive government initiatives, is driving the demand for allergy diagnostics in Europe. Besides, evolving technological landscape and favorable reimbursement policies also contribute to the market growth.

Product Code: 5621

Chapter 1 Methodology

1.1 Industry coverage
1.2 Market scope & definitions
1.3 Base estimates & working
- 1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact at global level
1.6 Data validation
1.7 Data sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Allergy diagnostics industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Product & service trends
- 2.1.4 Test type trends
- 2.1.5 Allergen trends
- 2.1.6 End-use trends

Chapter 3 Allergy Diagnostics Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence and high economic burden of allergic diseases
  - 3.2.1.2 Growing pollution levels coupled with rise in respiratory disorders
  - 3.2.1.3 Technological advancements in new products
  - 3.2.1.4 Rise in funding for allergy diagnostics companies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of allergy diagnostic instruments
  - 3.2.2.2 Limited awareness related to allergic diseases
3.3 Growth potential analysis
- 3.3.1 By product & service
- 3.3.2 By test type
- 3.3.3 By allergen
- 3.3.4 By end-use
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
- 3.5.1 U.S.
- 3.5.2 Europe
3.6 Reimbursement scenario
3.7 Technology landscape
3.8 Evolution of diagnostic allergen testing
3.9 Future market trends
3.10 Epidemiology scenario
3.11 Patent landscape
3.12 Porter's analysis
3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix
4.4 Vendor matrix analysis
4.5 Company market share analysis
4.6 Strategy dashboard, 2022

Chapter 5 Allergy Diagnostics Market Size and Forecast, By Product & Service (USD Million)

5.1 Key product & service trends
5.2 Consumables
5.3 Instruments
5.4 Services

Chapter 6 Allergy Diagnostics Market Size and Forecast, By Test Type (USD Million)

6.1 Key test type trends
6.2 In vivo
- 6.2.1 Skin Prick Tests
- 6.2.2 Intradermal Skin Test
- 6.2.3 Others
6.3 In vitro

Chapter 7 Allergy Diagnostics Market Size and Forecast, By Allergen (USD Million)

7.1 Key allergen trends
7.2 Inhaled Allergens
7.3 Food Allergens
7.4 Drug Allergens
7.5 Other Allergens

Chapter 8 Allergy Diagnostics Market Size and Forecast, By End-use (USD Million)

8.1 Key end-use trends
8.2 Hospital-based Laboratories
8.3 Diagnostic Laboratories
8.4 Others

Chapter 9 Allergy Diagnostics Market Size and Forecast, By Region (USD Million)

9.1 Key regional trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Poland
- 9.3.7 Sweden
- 9.3.8 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Indonesia
- 9.4.7 Philippines
- 9.4.8 Vietnam
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Columbia
- 9.5.5 Chile
- 9.5.6 Peru
9.6 MEA
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Turkey
- 9.6.5 Israel
- 9.6.6 Iran

Chapter 10 Company Profiles

10.1 Danaher Corporation
10.2 Thermo Fisher Scientific Inc.
10.3 Omega Diagnostics Group PLC
10.4 Siemens Healthcare Diagnostics, Inc.
10.5 Stallergenes SA
10.6 Hitachi Chemical Diagnostic Inc.
10.7 Lincoln Diagnostics, Inc.
10.8 Eurofins Scientific
10.9 Minaris Medical America, Inc.
10.10 EUROIMMUN Medizinische Labordiagnostika AG
10.11 bioMerieux SA
10.12 HOB Biotech Group Corp., Ltd.
10.13 R-Biopharm AG
10.14 HYCOR Biomedical
10.15 Neogen Corporation